{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:51:16Z","timestamp":1790783476046,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated controlled blood-brain barrier (BBB) disruption using a low-frequency clinical transcranial MRI-guided focused ultrasound (TcMRgFUS) device and evaluated enhanced delivery of irinotecan chemotherapy to the brain and a rat glioma model. Animals received three weekly sessions of FUS, FUS and 10\u2009mg\/kg irinotecan, or irinotecan alone. In each session, four volumetric sonications targeted 36 locations in one hemisphere. With feedback control based on recordings of acoustic emissions, 98% of the sonication targets (1045\/1071) reached a pre-defined level of acoustic emission, while the probability of wideband emission (a signature for inertial cavitation) was than 1%. BBB disruption, evaluated by mapping the R1 relaxation rate after administration of an MRI contrast agent, was significantly higher in the sonicated hemisphere (P\u2009&lt;\u20090.01). Histological evaluation found minimal tissue effects. Irinotecan concentrations in the brain were significantly higher (P\u2009&lt;\u20090.001) with BBB disruption, but SN-38 was only detected in &lt;50% of the samples and only with an excessive irinotecan dose. Irinotecan with BBB disruption did not impede tumor growth or increase survival. Overall these results demonstrate safe and controlled BBB disruption with a low-frequency clinical TcMRgFUS device. While irinotecan delivery to the brain was not neurotoxic, it did not improve outcomes in the F98 glioma model.<\/jats:p>","DOI":"10.1038\/s41598-020-65617-6","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T10:02:27Z","timestamp":1590746547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system"],"prefix":"10.1038","volume":"10","author":[{"given":"Nathan","family":"McDannold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey G.","family":"Supko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanikarn","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Vykhodtseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"Golby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"65617_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1148\/radiol.2202001804","volume":"220","author":"K Hynynen","year":"2001","unstructured":"Hynynen, K., McDannold, N., Vykhodtseva, N. & Jolesz, F. A. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220, 640\u2013646 (2001).","journal-title":"Radiology"},{"key":"65617_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neuroimage.2004.06.046","volume":"24","author":"K Hynynen","year":"2005","unstructured":"Hynynen, K., McDannold, N., Sheikov, N. A., Jolesz, F. A. & Vykhodtseva, N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 24, 12\u201320 (2005).","journal-title":"Neuroimage"},{"key":"65617_CR3","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1158\/0008-5472.CAN-12-0128","volume":"72","author":"N McDannold","year":"2012","unstructured":"McDannold, N., Arvanitis, C. D., Vykhodtseva, N. & Livingstone, M. S. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res 72, 3652\u20133663 (2012).","journal-title":"Cancer Res"},{"key":"65617_CR4","doi-asserted-by":"publisher","first-page":"163704","DOI":"10.1063\/1.3580763","volume":"98","author":"YS Tung","year":"2011","unstructured":"Tung, Y. S., Marquet, F., Teichert, T., Ferrera, V. & Konofagou, E. E. Feasibility of noninvasive cavitation-guided blood-brain barrier opening using focused ultrasound and microbubbles in nonhuman primates. Appl Phys Lett 98, 163704 (2011).","journal-title":"Appl Phys Lett"},{"key":"65617_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3171\/2013.5.JNS122374","volume":"119","author":"K Beccaria","year":"2013","unstructured":"Beccaria, K. et al. Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits. J. Neurosurg 119, 887\u2013898 (2013).","journal-title":"J. Neurosurg"},{"key":"65617_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aaf6086","volume":"8","author":"A Carpentier","year":"2016","unstructured":"Carpentier, A. et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci. Transl. Med 8, 1\u20139 (2016).","journal-title":"Sci. Transl. Med"},{"key":"65617_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36340-0","volume":"9","author":"T Mainprize","year":"2019","unstructured":"Mainprize, T. et al. Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study. Sci. Rep 9, 321 (2019).","journal-title":"Sci. Rep"},{"key":"65617_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04529-6","volume":"9","author":"N Lipsman","year":"2018","unstructured":"Lipsman, N. et al. Blood-brain barrier opening in Alzheimer\u2019s disease using MR-guided focused ultrasound. Nat Commun 9, 2336 (2018).","journal-title":"Nat Commun"},{"key":"65617_CR9","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1038\/jcbfm.2012.100","volume":"32","author":"B Marty","year":"2012","unstructured":"Marty, B. et al. Dynamic study of blood-brain barrier closure after its disruption using ultrasound: a quantitative analysis. J Cereb. Blood Flow Metab 32, 1948\u20131958 (2012).","journal-title":"J Cereb. Blood Flow Metab"},{"key":"65617_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.addr.2014.01.008","volume":"72","author":"M Aryal","year":"2014","unstructured":"Aryal, M., Arvanitis, C. D., Alexander, P. M. & McDannold, N. Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv. Drug Deliv. Rev 72, 94\u2013109 (2014).","journal-title":"Adv. Drug Deliv. Rev"},{"key":"65617_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1148\/radiol.10090699","volume":"255","author":"HL Liu","year":"2010","unstructured":"Liu, H. L. et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 255, 415\u2013425 (2010).","journal-title":"Radiology"},{"key":"65617_CR12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.7863\/jum.2009.28.7.871","volume":"28","author":"J Mei","year":"2009","unstructured":"Mei, J. et al. Experimental study on targeted methotrexate delivery to the rabbit brain via magnetic resonance imaging-guided focused ultrasound. J. Ultrasound Med 28, 871\u2013880 (2009).","journal-title":"J. Ultrasound Med"},{"key":"65617_CR13","doi-asserted-by":"publisher","first-page":"e58995","DOI":"10.1371\/journal.pone.0058995","volume":"8","author":"KC Wei","year":"2013","unstructured":"Wei, K. C. et al. Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. Plos One 8, e58995 (2013).","journal-title":"Plos One"},{"key":"65617_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jconrel.2013.04.007","volume":"169","author":"M Aryal","year":"2013","unstructured":"Aryal, M., Vykhodtseva, N., Zhang, Y. Z., Park, J. & McDannold, N. Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model. J Control Release 169, 103\u2013111 (2013).","journal-title":"J Control Release"},{"key":"65617_CR15","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3171\/2015.4.JNS142893","volume":"124","author":"K Beccaria","year":"2016","unstructured":"Beccaria, K. et al. Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits. J. Neurosurg 124, 1602\u20131610 (2016).","journal-title":"J. Neurosurg"},{"key":"65617_CR16","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1056\/NEJMoa1600159","volume":"375","author":"WJ Elias","year":"2016","unstructured":"Elias, W. J. et al. A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor. N. Engl. J. Med 375, 730\u2013739 (2016).","journal-title":"N. Engl. J. Med"},{"key":"65617_CR17","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1088\/0031-9155\/55\/18\/001","volume":"55","author":"MA O\u2019Reilly","year":"2010","unstructured":"O\u2019Reilly, M. A., Huang, Y. & Hynynen, K. The impact of standing wave effects on transcranial focused ultrasound disruption of the blood-brain barrier in a rat model. Phys Med Biol 55, 5251\u20135267 (2010).","journal-title":"Phys Med Biol"},{"key":"65617_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3174\/ajnr.A3150","volume":"34","author":"KC Wei","year":"2013","unstructured":"Wei, K. C. et al. Neuronavigation-guided focused ultrasound-induced blood-brain barrier opening: a preliminary study in swine. AJNR Am. J. Neuroradiol 34, 115\u2013120 (2013).","journal-title":"AJNR Am. J. Neuroradiol"},{"key":"65617_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1148\/radiol.2016152154","volume":"282","author":"Y Huang","year":"2017","unstructured":"Huang, Y., Alkins, R., Schwartz, M. L. & Hynynen, K. Opening the Blood-Brain Barrier with MR Imaging-guided Focused Ultrasound: Preclinical Testing on a Trans-Human Skull Porcine Model. Radiology 282, 123\u2013130 (2017).","journal-title":"Radiology"},{"key":"65617_CR20","doi-asserted-by":"crossref","unstructured":"McDannold, N. et al. Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model. Theranostics, in press (2019).","DOI":"10.7150\/thno.35892"},{"key":"65617_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/RLI.0000000000000132","volume":"50","author":"Y Shen","year":"2015","unstructured":"Shen, Y. et al. T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radiol 50, 330\u2013338 (2015).","journal-title":"Invest Radiol"},{"key":"65617_CR22","unstructured":"Lele, P. P. In Ultrasound: Medical Applications, Biological Effects and Hazard Potential (eds M.H. Repacholi, M. Grondolfo, & A. Rindi) 275-306 (Plenum Pub. Corp., 1987)."},{"key":"65617_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jconrel.2015.02.033","volume":"204","author":"M Aryal","year":"2015","unstructured":"Aryal, M., Vykhodtseva, N., Zhang, Y. Z. & McDannold, N. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: A safety study. J. Control Release 204, 60\u201369 (2015).","journal-title":"J. Control Release"},{"key":"65617_CR24","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.ultrasmedbio.2005.07.010","volume":"31","author":"N McDannold","year":"2005","unstructured":"McDannold, N., Vykhodtseva, N., Raymond, S., Jolesz, F. A. & Hynynen, K. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: Histological findings in rabbits. Ultrasound in Medicine and Biology 31, 1527\u20131537 (2005).","journal-title":"Ultrasound in Medicine and Biology"},{"key":"65617_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3171\/jns.2006.105.3.445","volume":"105","author":"K Hynynen","year":"2006","unstructured":"Hynynen, K. et al. Focal disruption of the blood\u2013brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J. Neurosurgery 105, 445\u2013454 (2006).","journal-title":"J. Neurosurgery"},{"key":"65617_CR26","doi-asserted-by":"crossref","unstructured":"Kobus, T., Vykhodtseva, N., Pilatou, M., Zhang, Y. & McDannold, N. Safety Validation of Repeated Blood-Brain Barrier Disruption Using Focused Ultrasound. Ultrasound Med. Biol (2015).","DOI":"10.1016\/j.ultrasmedbio.2015.10.009"},{"key":"65617_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1021\/cn9000445","volume":"1","author":"R Chopra","year":"2010","unstructured":"Chopra, R., Vykhodtseva, N. & Hynynen, K. Influence of exposure time and pressure amplitude on blood-brain-barrier opening using transcranial ultrasound exposures. ACS Chem. Neurosci 1, 391\u2013398 (2010).","journal-title":"ACS Chem. Neurosci"},{"key":"65617_CR28","doi-asserted-by":"publisher","first-page":"E75","DOI":"10.1073\/pnas.1614777114","volume":"114","author":"ZI Kovacs","year":"2017","unstructured":"Kovacs, Z. I. et al. Disrupting the blood-brain barrier by focused ultrasound induces sterile inflammation. Proc Natl. Acad. Sci. U. S. A 114, E75\u2013E84 (2017).","journal-title":"Proc Natl. Acad. Sci. U. S. A"},{"key":"65617_CR29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1088\/0031-9155\/51\/4\/003","volume":"51","author":"N McDannold","year":"2006","unstructured":"McDannold, N., Vykhodtseva, N. & Hynynen, K. Targeted disruption of the blood-brain barrier with focused ultrasound: association with cavitation activity. Phys. Med. Biol 51, 793\u2013807 (2006).","journal-title":"Phys. Med. Biol"},{"key":"65617_CR30","doi-asserted-by":"publisher","first-page":"e45783","DOI":"10.1371\/journal.pone.0045783","volume":"7","author":"CD Arvanitis","year":"2012","unstructured":"Arvanitis, C. D., Livingstone, M. S., Vykhodtseva, N. & McDannold, N. Controlled ultrasound-induced blood-brain barrier disruption using passive acoustic emissions monitoring. Plos One 7, e45783 (2012).","journal-title":"Plos One"},{"key":"65617_CR31","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1088\/0031-9155\/55\/20\/007","volume":"55","author":"YS Tung","year":"2010","unstructured":"Tung, Y. S. et al. In vivo transcranial cavitation threshold detection during ultrasound-induced blood-brain barrier opening in mice. Phys Med Biol 55, 6141\u20136155 (2010).","journal-title":"Phys Med Biol"},{"key":"65617_CR32","doi-asserted-by":"publisher","first-page":"9079","DOI":"10.1088\/0031-9155\/60\/23\/9079","volume":"60","author":"T Sun","year":"2015","unstructured":"Sun, T. et al. Acoustic cavitation-based monitoring of the reversibility and permeability of ultrasound-induced blood-brain barrier opening. Phys. Med. Biol 60, 9079\u20139094 (2015).","journal-title":"Phys. Med. Biol"},{"key":"65617_CR33","doi-asserted-by":"publisher","first-page":"E10281","DOI":"10.1073\/pnas.1713328114","volume":"114","author":"T Sun","year":"2017","unstructured":"Sun, T. et al. Closed-loop control of targeted ultrasound drug delivery across the blood-brain\/tumor barriers in a rat glioma model. Proc Natl. Acad. Sci. U. S. A 114, E10281\u2013E10290 (2017).","journal-title":"Proc Natl. Acad. Sci. U. S. A"},{"key":"65617_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1148\/radiol.11111417","volume":"263","author":"MA O\u2019Reilly","year":"2012","unstructured":"O\u2019Reilly, M. A. & Hynynen, K. Blood-Brain Barrier: Real-time Feedback-controlled Focused Ultrasound Disruption by Using an Acoustic Emissions-based Controller. Radiology 263, 96\u2013106 (2012).","journal-title":"Radiology"},{"key":"65617_CR35","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.neuro.2006.03.002","volume":"27","author":"BS Jortner","year":"2006","unstructured":"Jortner, B. S. The return of the dark neuron. A histological artifact complicating contemporary neurotoxicologic evaluation. Neurotoxicology 27, 628\u2013634 (2006).","journal-title":"Neurotoxicology"},{"key":"65617_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1215\/15228517-2008-075","volume":"11","author":"JJ Vredenburgh","year":"2009","unstructured":"Vredenburgh, J. J., Desjardins, A., Reardon, D. A. & Friedman, H. S. Experience with irinotecan for the treatment of malignant glioma. Neuro. Oncol 11, 80\u201391 (2009).","journal-title":"Neuro. Oncol"},{"key":"65617_CR37","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1517\/14656566.2011.566558","volume":"12","author":"JN Jakobsen","year":"2011","unstructured":"Jakobsen, J. N., Hasselbalch, B., Stockhausen, M. T., Lassen, U. & Poulsen, H. S. Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert. Opin. Pharmacother 12, 825\u2013833 (2011).","journal-title":"Expert. Opin. Pharmacother"},{"key":"65617_CR38","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh, J. J. et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol 25, 4722\u20134729 (2007).","journal-title":"J. Clin. Oncol"},{"key":"65617_CR39","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3171\/2010.2.JNS09719","volume":"114","author":"W Wang","year":"2011","unstructured":"Wang, W. et al. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation. J. Neurosurg 114, 689\u2013694 (2011).","journal-title":"J. Neurosurg"},{"key":"65617_CR40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ejca.2011.04.033","volume":"48","author":"SA Choi","year":"2012","unstructured":"Choi, S. A. et al. Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. Eur J Cancer 48, 129\u2013137, https:\/\/doi.org\/10.1016\/j.ejca.2011.04.033 (2012).","journal-title":"Eur J Cancer"},{"key":"65617_CR41","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.18632\/oncotarget.3627","volume":"6","author":"V Staedtke","year":"2015","unstructured":"Staedtke, V. et al. Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats. Oncotarget 6, 5536\u20135546, https:\/\/doi.org\/10.18632\/oncotarget.3627 (2015).","journal-title":"Oncotarget"},{"key":"65617_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11060-009-9875-7","volume":"94","author":"RF Barth","year":"2009","unstructured":"Barth, R. F. & Kaur, B. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol 94, 299\u2013312 (2009).","journal-title":"J Neurooncol"},{"key":"65617_CR43","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.ultrasmedbio.2011.08.001","volume":"37","author":"MA O\u2019Reilly","year":"2011","unstructured":"O\u2019Reilly, M. A., Muller, A. & Hynynen, K. Ultrasound insertion loss of rat parietal bone appears to be proportional to animal mass at submegahertz frequencies. Ultrasound Med Biol 37, 1930\u20131937 (2011).","journal-title":"Ultrasound Med Biol"},{"key":"65617_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0378-4347(94)00340-8","volume":"661","author":"LP Rivory","year":"1994","unstructured":"Rivory, L. P. & Robert, J. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J. Chromatogr. B Biomed Appl 661, 133\u2013141 (1994).","journal-title":"J. Chromatogr. B Biomed Appl"},{"key":"65617_CR45","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.mri.2012.06.011","volume":"30","author":"FM Fennessy","year":"2012","unstructured":"Fennessy, F. M. et al. Practical considerations in T1 mapping of prostate for dynamic contrast enhancement pharmacokinetic analyses. Magn Reson. Imaging 30, 1224\u20131233 (2012).","journal-title":"Magn Reson. Imaging"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65617-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65617-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65617-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T11:49:44Z","timestamp":1670327384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65617-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["65617"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-65617-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"11 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was partially supported via a sponsored research agreement with InSightec. Brigham and Women\u2019s Hospital holds patents on the use of focused ultrasound to disrupt the blood-brain barrier; Dr. McDannold is a coinventor on those patents. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8766"}}